Page last updated: 2024-08-21

quinazolines and gsk 461364

quinazolines has been researched along with gsk 461364 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Armeson, K; Britten, C; Erlander, M; Ethier, S; Giordano, A; Kappler, C; Liu, Y; Park, Y; Reuben, J; Ridinger, M; Yeh, E	1

Other Studies

1 other study(ies) available for quinazolines and gsk 461364

Article	Year
Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer. PloS one, 2019, Volume: 14, Issue:11 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Cycle Proteins; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Mice; Piperazines; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quinazolines; Thiophenes; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays	2019

Article

Year

Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer.

PloS one, 2019, Volume: 14, Issue:11

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Cycle Proteins; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Mice; Piperazines; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quinazolines; Thiophenes; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays

2019